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Tamoxifen (Nolvadex) is one of the most widely used and effective therapeutic agent
for breast cancer. It benefits nearly 75% of patients with estrogen receptor (ER)-positive
breast cancer that receive this drug. Its effectiveness is mainly attributed to its capacity
to function as an ER antagonist, blocking estrogen binding sites on the receptor, and
inhibiting the proliferative action of the receptor-hormone complex. Although, tamoxifen
can induce apoptosis in breast cancer cells via upregulation of pro-apoptotic factors,
it can also promote uterine hyperplasia in some women. Thus, tamoxifen as a multi-
functional drug could have different effects on cells based on the utilization of effective
concentrations or availability of specific co-factors. Evidence that tamoxifen functions
as a GPR30 (G-Protein Coupled Receptor 30) agonist activating adenylyl cyclase and
EGFR (Epidermal Growth Factor Receptor) intracellular signaling networks, provides yet
another means of explaining the multi-functionality of tamoxifen. Here ordinary differential
equation (ODE) modeling, RNA sequencing and real time qPCR analysis were utilized to
establish the necessary data for gene network mapping of tamoxifen-stimulated MCF-
7 cells, which express the endogenous ER and GPR30. The gene set enrichment
analysis and pathway analysis approaches were used to categorize transcriptionally
upregulated genes in biological processes. Of the 2,713 genes that were significantly
upregulated following a 48 h incubation with 250 µM tamoxifen, most were categorized
as either growth-related or pro-apoptotic intermediates that fit into the Tp53 and/or
MAPK signaling pathways. Collectively, our results display that the effects of tamoxifen
on the breast cancer MCF-7 cell line are mediated by the activation of important
signaling pathways including Tp53 and MAPKs to induce apoptosis.
Keywords: tamoxifen, GPR30, ODE modeling, RNA sequencing, apoptosis, MCF-7
INTRODUCTION
Breast cancer is the second leading cause of cancer death in the United States in women after
lung cancer (Holt, 2010). Clinically, breast cancer is categorized as ER-alpha positive and ER-
negative (Haldosen et al., 2014), which dictates the treatment options. The GPR30 receptors are
well-known members of the large family of GPCR (G protein–coupled receptors) receptors whose
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sequences are located in the 7P22.3 of human genome (Albanito
et al., 2008). These receptors are structurally different from
estrogen receptors (ER) and are expressed extensively within
early mammary tumors and in breast cancer cell lines (Prossnitz
et al., 2008; Prossnitz and Barton, 2009). Activation of the GPR30
signaling cascade mediates the non-genomic route of estrogen
hormones and stimulates the PI3K/Akt and MAPK (Mitogen-
Activated Protein Kinase) signaling intermediates. Thus, this
pathway controls different cellular processes that can culminate
in cell proliferation, migration, differentiation, and apoptosis
(Filardo et al., 2000; Ge et al., 2012; Luo et al., 2012). Besides
interacting with estrogenic hormones, the receptor GPR30 also
has a tendency to bind a number of anti-estrogenic compounds
such as tamoxifen and ICI182780 (Thomas et al., 2005).
Tamoxifen is a non-steroidal compound that is used
extensively in patients with ER+ breast cancer. In addition to its
beneficial effects in reducing metastasis, tamoxifen can also lower
the risk of death from breast cancer (Jordan, 2006; Jordan and
O’Malley, 2007). Studies have shown that at low concentrations,
tamoxifen represses the cell cycling process, while at higher
concentration it induces cell apoptosis (Osborne et al., 1983;
Perry et al., 1995; Chen et al., 1996; Otto et al., 1996).
Activation of the GPR30 signaling pathway can stimulate the
PI3K and MAPK signaling pathways. In this way, after binding
of the ligand to the GPR30 receptor, the subunit Gα separates
from the subunit Gβγ, and can activate the adenylyl cyclase and
phospholipase C. The Gβγ subunit itself activates the Src-like
tyrosine kinase protein, which induces the phosphorylation of
Shc protein and activates the matrix-metalloproteases (MMPs).
The activated MMPs trigger the transactivation of EGFR
receptor by cleaving the HB-EGF (Heparin Binding EGF) in
the membrane, and ultimately releasing EGF. This leads to
temporary activation of ERKs, which subsides after the signal
diminishes (Luttrell et al., 1999; Filardo et al., 2000; Filardo,
2002).
The Ras/Raf/ERKs signaling pathway is one of the most
commonly deregulated pathways in a variety of tumors. Many
studies have shown that, depending on the duration and its
subcellular localization, ERK activity controls various cellular
responses such as proliferation, migration, differentiation, and
apoptosis (Murphy and Blenis, 2006). Apoptosis is triggered by
certain conditions including hyperactivity of ERKs. Interestingly,
Abbreviations: AKT, AKT serine/threonine kinase; BAK, BCL2 Antagonist/Killer
1; BAX, BCL2 Associated X; CASP3, caspase 3; CASP8, caspase 8; CDKN1A,
cyclin dependent kinase inhibitor 1A; CYCS, cytochrome C, somatic; DAG,
diacylglycerol; EGF, epidermal growth factor; FAS, Fas Cell Surface Death
Receptor; GADD45A, growth arrest and DNA damage inducible alpha; GADD45B,
growth arrest and DNA damage inducible beta; GADD45G, growth arrest and
DNA damage inducible gamma; GORAB, golgin, RAB6 interacting; Grb-2,
growth factor receptor bound protein 2; GREB, growth regulation by estrogen
in breast cancer; IP3, inositol triphosphate; ITGAV, integrin subunit alpha V;
JAK, Janus kinase; LMNA, Lamin A/C; NF1, neurofibromin 1; PARP, poly(ADP-
ribose) polymerase; PI3K, phosphoinositide-3-kinase; PKC, protein kinase C; PLC,
phospholipase C; PMAIP1, phorbol-12-myristate-13-acetate-induced protein 1;
PPM1D, protein phosphatase, Mg2+/Mn2+ dependent 1D; PTEN, phosphatase
and tensin homolog; PUMA, P53 up-regulated modulator of apoptosis; RARA,
retinoic acid receptor alpha; RCHY1, ring finger and CHY zinc finger domain
containing 1; RTK, receptor tyrosine kinase; SESN, sestrin; SFN, stratifin; STAT,
signal transducer and activator of transcription; TNFRSF10B, TNF receptor
superfamily member 10b; ZMAT3, zinc finger matrin-type 3.
active ERK can be located within the mitochondrial membrane
and facilitate the cytochrome c entrance into the cytoplasm
by disrupting the mitochondrial membrane (Leeman et al.,
2006). Also, the MEK/ERKs pathway activity can upregulate the
pro-apoptotic members of Bcl-2 family such as Bax, PUMA,
and Bak as well as down regulate the anti-apoptotic members
of the family such as Bcl-2 and Bcl-XL (Li et al., 2007; Liu
et al., 2008; Panaretakis et al., 2008). In addition, ERK-dependent
over-activation of Tp53 protein leads to phosphorylation of
serine 15 residue in Tp53, and inhibits the Mdm2 interaction
with Tp53. This results in accumulation of Tp53. Studies have
shown that ERK can phosphorylate threonine 55 residue of Tp53,
increasing its binding to DNA and down regulating Bcl-2 gene
expression (Persons et al., 2000; She et al., 2000). Overall, these
data suggest that sustained ERK activity in some cellular regions
is not tolerated and leads to different forms of cell death (Cagnol
and Chambard, 2010).
In the current study, we aimed to simulate the
GPR30/PI3K/MAPK/STAT signaling pathway in normal
and cancer cells by the use of ordinary differential equation
(ODE) modeling. In addition, we planned to show that MAPK
activation pattern is different between normal and cancer models.
We also assessed the activity of ERK in tamoxifen-treated and
untreated cells using RNA-sequencing and real time RT-PCR
(qPCR) methods. The expression level of the known apoptosis
signaling intermediates were examined in the MCF-7 cells
incubated with tamoxifen to ascertain the relationship between
tamoxifen-induced MAPK signaling pathway and induction of
apoptosis in these cells.
MATERIALS AND METHODS
Materials
Roswell Park Memorial Institute Medium 1640 (RPMI 1640),
tamoxifen citrate salt, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide (MTT) and Dimethyl sulfoxide were all
obtained from Sigma (United States). Fetal bovine serum (FBS)
was from Invitrogen (United States). Annexin-V-FLUOS Staining
Kit, TriPure Isolation Reagent, Streptomycin and penicillin,
Propidium Iodide (PI) kit, 4,6-diamidino-2-phenylindole (DAPI)
kit were provided from Roche (Germany). RealQ Plus Master
Mix Green was provided from Ampliqon (Denmark). cDNA
generation was carried out with RevertAid First Strand cDNA
Synthesis kit by Thermo Scientific (United States).
Computational Modeling of Signaling
Pathway
Modeling is one of the branches of system biology, which is able
to simulate a simple or a series of related reactions within an
organism based on mathematical equations. Using this approach,
the biological events could easily transform into quantitative
data and subsequent analysis. ODE is one of the most widely
used methods for modeling a bionetwork. In general, the ODE
relationship represents how the concentration of a substrate
changes over time (Kitano, 2002; Kirschner, 2005; Bidkhori et al.,
2012).
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One of the most exciting developments in signal transduction
research is the use of mathematical models and computer
simulation in the field of pharmacology and drug discovery.
Signal transduction networks are largely composed of proteins
which can interact, move to specific cellular locations, or
be modified or degraded. An advantage of ODE models is
that they describe the rate of change of continuous variables
which used for modeling dynamical systems in several areas
(Eungdamrong and Iyengar, 2004; Chen et al., 2010; Hughey
et al., 2010). In this work, mass-action laws are used to model
the dynamics of systems of chemical reactions, that is, reaction
networks.
For example, a substrate (S) is converted to the product (P)
with a constant rate (k1) that can be calculated by the Mass Action
Equation:
S k1→P v = k1[S]
This relationship shows a first-order reaction and indicates
the direct linkage between the reaction velocity (V) and
the first potential substrate concentration. In fact, the higher
concentration of substrate boosts the reaction rate and substrate
consumption resulting in faster production of the product (P)
(Chaudhury and Igoshin, 2010; Chen et al., 2010). According to
the above equations, the differential relations for substrate and
product will be as follows:
d[S]
dt
= −k1[S] or d[P]
dt
= k1[S]
To model the above reaction, it is important to know the initial
concentration of the substrates and the products. Plus, quadratic
reactions may also exist in these relationships. Thus, in these cases
the reactions have a direct relationship with the concentration
of two reactants. For modeling and simulating above reaction, it
is necessary to know S and P initial values. The reaction above
is called a first-order reaction. In such reactions, the rate is
relational to the value of a single reactant. On the other hand,
a second-order reaction is relational to the square of the value of
an individual reactant or two reactants:
S+ R k2→P and v= k2[S][R]
k1 and k2 are defined in S−1 and µM−1S−1 dimensions
respectively.
Our proposed model for the GPR30/EGFR/PI3K/STAT
signaling pathway is based on an ODE modeling, which includes
128 species, 143 reactions, 213 parameters and 1 rule. In
Supplementary Table S1, reactions are shown for this signaling
pathway. To simulate the ODE15s routine, the MATLAB 7.9.0
was used to determine the differential equations. The systems
biology markup language (SBML) of our models is provided in
Supplementary File S1 (untreated model) and Supplementary
File S2 (tamoxifen-treated model). SBML is a computer-
readable XML format for representing models of biochemical
reaction which allows models of arbitrary complexity to be
represented.
The following relationship is an example of the assessment of
simulated reactions using the ODE method in this paper:
Akt+ PIP3
k1
→
←
kr1
Aktm
v = k1[Akt][PIP3] − kr1[Aktm]
Where k1 is the rate constant for the forward direction and kr1 is
for the reverse one.
Cell Culture and Treatment
Human breast cancer cell line, MCF7 cells (ATCC R© HTB-22TM),
were purchased from Iranian Biological Resource Center
(Tehran, Iran). Cells were cultured in RPMI-1640 medium
(Sigma, United States) containing 100 µg/ml penicillin,
100 µg/ml streptomycin, 2 mM glutamine, 10% heat-inactivated
FBS (Invitrogen, United States), and incubated at 37◦C in
a humidified 5% CO2 incubator. Heat-inactivation (heating
to 56◦C for 30 min) is done to inactivate complement, a
group of proteins present in sera that are part of the immune
response. This is sometimes important for cells that will be
used to prepare or assay viruses, or cells that are used in
cytotoxicity assays or other systems where complement may
have an unwanted influence. In our work, heat-inactivated
serum was used in the experimental medium in order to
inactivate complement and diminish the content of estrogens.
According to MTT assay, the LC50 of tamoxifen after 48 h
was determined as 250 µM. Tamoxifen was dissolved in
DMSO and then added to culture medium to the final desired
concentration based on the determined LC50 and filtered. Cells
(at 80% confluency) were incubated with freshly prepared drugs
for 48h in a humidified incubator before being trypsinized
and washed with phosphate-buffered saline three times and
stored at−70◦C.
MTT Assay (Cytotoxicity/Viability Assay)
Cell viability was assessed after tamoxifen treatment using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT). Twenty microliter of 0.5-mg/mL concentration of MTT
stock (diluted in PBS, pH 7.2) was added to the culture medium
and cells were incubated at 37◦C with 5% CO2 for 3 h. Next, the
cells were incubated with 200 µl of dimethyl sulfoxide (DMSO;
Sigma) for an additional 5 min, and their viability was measured
using a microplate reader (Rayto-China) at 570 nm. The MTT
assays were performed at least three times for each concentration
of drug and the percentage of surviving cells relative to control
(untreated sample) was determined.
Quantification of Cell Cycle Distributions
and Apoptosis by Flow Cytometry
Flow cytometry was used for the evaluation of apoptosis in
treated cells. Annexin V-FITC and propodium iodide (PI)
staining was performed using Annexin-V-FLUOS and PI staining
kit, followed by flow cytometry using a Becton Dickinson
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instrument (United Kingdom). Cells were incubated with
250 µM of Tamoxifen for 48 h. Cells (106) were washed in
PBS and suspended in 100 µl Annexin/PI buffer (20 µl of each
Annexin and PI buffer in 1 ml of incubation buffer) for 10–15 min
at 25◦C. After dilution in 500µl of incubation buffer, fluorescence
was measured at excitation and emission wavelengths of 518
and 617 nm, respectively. Cell cycle distribution was determined
using the DAPI staining kit. Cells (5 × 105) were incubated
with 1 ml of fluorochrome solution (10 µg/ml, DAPI; and 6%
triton X-100 in PBS) in the dark for 30 min at 4◦C. Fluorescence
was recorded at excitation and emission wavelengths of 359 and
461 nm, respectively, using the Becton Dickinson flow cytometer.
Data was analyzed on 2-dimensional curves (number of cells
against area under the peak), using FlowJo software.
RNA Extraction
Total RNA was extracted from the cells using TriPure Isolation
Reagent (Roche Diagnostics GmbH, Germany) according to
the kit’s protocol. To avoid genomic DNA contamination, the
RNA samples were treated with DNase for one hour. The
RNA concentration was measured using a Nano drop ND-1000
spectrophotometer (Nano drop Technologies), and the purity
was assayed by measuring the A260/A280 ratio, which was
expected to be 1.8–2.0.
cDNA Library Construction and RNA
Sequencing
Following RNA isolation, creation of an RNA-seq library is
the next step in transcriptome sequencing. The preparation
of intended cDNA libraries and paired-end sequencing were
performed by the Beijing Genome Institute (BGI), China. In total,
four cDNA paired-end libraries were generated for transcriptome
sequencing on Illumina HiSeqTM 2000 platform.
Briefly, rRNA depletion methods were used for library
construction. Based on the protocol, after rRNA depletion all
other RNAs with or without the polyA sequence were subjected
to adaptor ligation. The adapter-ligated templates were purified
by the Agencourt AMPure SPRI beads and fragments with insert
size about 200 bp were excised and used to synthesize the first
strand cDNA. The second-strand cDNA was synthesized using
dNTPs, RNaseH and DNA polymerase I. Suitable fragments were
amplified by ligation-mediated polymerase chain reaction (LM-
PCR), purified, and hybridized to the SureSelect Biotinylated
RNA Library (BAITS) for enrichment. Hybridized fragments
were bound to the streptavidin beads whereas non-hybridized
fragments were washed out after 24 h. Captured LM-PCR
products were subjected to Agilent 2100 Bio analyzer to
estimate the magnitude of enrichment. Each captured library
was then loaded on HiSeq 2000 platform, and subjected to high-
throughput sequencing for each captured library independently
to ensure that each sample met the desired average fold-coverage.
Raw image files were processed by Illumina base calling Software
1.7 for base calling with default parameters and the sequences of
each individual were generated as 90 bp paired-end reads. The
obtained raw data were subjected to the GO analysis (version 6.8,
2016) and KEGG mapping for pathway analysis of the screened
DEGs. The data discussed in this publication have been deposited
in the Gene Expression Omnibus (GEO) database, https://www.
ncbi.nlm.nih.gov/geo and are accessible through GEO Series
accession number GSE115737.
Reverse Transcription and Quantitative
Real-Time PCR Analysis (RT-qPCR)
RNA samples (2 µg) were subjected to cDNA synthesis by the
RevertAid First Strand cDNA Synthesis kit. The cDNA samples
were amplified using the RealQ Plus Master Mix Green Kit with
QIAGEN’s real-time PCR cycler, the Rotor-Gene Q with an initial
denaturation at 95◦C for 15 min followed by 45 cycles each 95◦C
for 15 s, 62◦C for 10 s, and 72◦C for 20 s. Relative expression
abundance of targets were determined by Relative expression
software tool (REST) for group-wise comparison and statistical
analysis of relative expression results in real-time PCR.
Statistical Analysis
Distribution and quality of the RNA-seq data sets were assessed
using various statistical methods. Using the formula: Phred
Quality (Q) score = −10log2E, the error rate of data sets was
calculated (E stands for error rate). Guanine-cytosine (GC)
pairs distribution were determined and the homogeneity of the
sequences was confirmed. The unwilling raw reads were excluded
from subsequent analysis including adaptor sequences, reads
with low quality, raw reads contain more than 20% N bases or
those with more than 50% N bases that achieved the Q-score
above the 20.
The Cuﬄinks software (version 2.2.1, 2014) was applied to
evaluate the expression level of intended genes. The expression
score was calculated by the formula: RPKM = total exon
reads/mapped reads in millions × exon length in kb, which
RPKM stands for reads per kilobase of transcript per million
mapped reads. Also, using the DESeq software (version 1.12.1,
2016) the difference between experimental groups was analyzed.
Comparisons between the groups were made by a one-
way analysis of variance (ANOVA) followed by an appropriate
post hoc test to analyze the difference. All data are represented
as the mean ± SD (Standard deviation). The P-values correction
was done by the Benjamini–Hochberg multiple testing. Statistical
significance was achieved when P and q values were <0.05.
All statistical analyses were performed with IBM SPSS Statistics
software version 22 (IBM, United States).
RESULTS
Construction of a Model for ERK
Activation Through GPR30 Axis
The designed signaling network for normal cells is modeled based
on the experimental evidences and previous models of the EGFR,
PI3K, STAT and GPCR signaling pathways (Schoeberl et al., 2002;
Yamada et al., 2003, 2004; Sasagawa et al., 2005; Heitzler et al.,
2012). This network consists of four main pathways (Figure 1),
which play important roles in cell proliferation, differentiation,
and apoptosis. These pathways are activated through two ligands
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FIGURE 1 | Schematic overview of the GPR30/EGFR/PI3K/STAT signaling axis. This network consists of the interaction between GPR30/PI3K/MAPK/STAT
pathways. Initial stimulation by tamoxifen causes activation of GPR30 receptors and activation of PLC by releasing the Gβγ subunit which can trigger ERK activation.
Also, src can activate MMPs which can convert HB-EGF to EGF. EGF can bind and activate EGFR, causing receptor dimerization and cross-phosphorylation of
tyrosine residues in the intracellular domains. The activated EGFR axis can phosphorylate ERK and through that regulates various cell processes. PI3K and JAK can
be recruited to cell membrane by interaction with EGFR phosphotyrosine docking sites. PI3K subsequently causes AKT activation and regulates cell growth and
survival. Activation of STAT dimers by JAK play a key role in controlling cell growth and survival. Since JAK-STAT signaling can allow the transcription of genes
involved in cell division, one potential effect of excessive JAK-STAT signaling is cancer formation.
alongside the two axes: 1- through the EGF binding to EGFR, and
2- via tamoxifen binding to GPR30 (Supplementary Table S1).
After binding of EGF to EGFR, the receptor is formed
into the hetero- or homo-dimeric state, which leads to auto
phosphorylation of tyrosine resides including pY992, pY1068 and
pY1173 at the C-terminal region (Walton et al., 1990). Proteins
such as Grb2, Shc and STAT can bind to the phosphorylated
tyrosine residues. Following C-terminal phosphorylation of
EGFR, the Shc protein is bound and provokes Grb2 and SOS
accumulation. Grb2 can interact with the receptor alone and
invoke SOS recruitment. SOS then converts Ras-GDP into Ras-
GTP, which is the active form of Ras. The Ras-GTP binds to the
serine/threonine kinase Raf and activates it. Subsequently, Raf
stimulates MEK (MAP kinase kinase) via phosphorylation. The
activated MEK phosphorylates ERK and through that regulates
various cell processes such as cell growth or death (Marais et al.,
1995; Wiley et al., 2003; Steelman et al., 2011).
The PI3K has a regulatory subunit (85 kDa) along with
a catalytic subunit (110 kDa). After phosphorylation and
activation of EGFR, the regulatory subunit connects to the
phosphorylated tyrosine residue, then catalytic subunit is
bound to the regulatory unit and induces the membrane
Phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] conversion
into the Phosphatidylinositol (3,4,5)-trisphosphate [PI(3,4,5)P3].
Next, the PI3,4,5P3 binds and stimulates the PDK1 protein to
phosphorylate AKT. AKT regulates cell growth and survival in
a direct or an indirect manner. Negative adjustment of PI3K
as well as deactivation of AKT are accomplished by the protein
phosphatase PTEN, which converts PI(3,4,5)P3 into PI(4,5)P2
and subsequently causes AKT suppression (Franke et al., 1997;
Silva et al., 2008).
Signal transducer and activator of transcription are specific
transcription factors that act as downstream effectors in the
cytokine and growth factor receptors signaling pathways. STAT
proteins can directly bind EGFR via their SH2 domains and form
active phosphorylated dimers. STAT dimers play a key role in
controlling cell growth and survival by regulation of the target
genes (Leeman et al., 2006; Mertens and Darnell, 2007).
The other axis of our model consisted of the GPR30 receptor
signaling pathway. The GPR30 is activated by binding of the
tamoxifen and boosts the activation of PLC by releasing the
Gβγ subunit. PLC stimulates the IP3 and DAG production from
the membrane PI(4,5)P2. Both IP3 and DAG activate PKC,
which can trigger ERK activation. The suppression of GPCR
(GPR30) is mediated by phosphorylation with the GRK. The
phosphorylation of GPR30 by GRK causes binding of β-arrestin
protein to the receptor and internalization of the formed
complex. This complex is separated into its constituent elements
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in the endosomes environment with low pH, and the receptor
subunit returns to the cell membrane after dephosphorylation.
Studies show that GRK families have different variants, as
some of them cause the formation of a complex and evoke
the β-arrestin 2 factor, which mediates the phosphorylation
of ERKs independent of the GPR30 receptors (Heitzler et al.,
2012).
ODE Modeling and Comparison of ERK
Activity in the Experimental Groups
ERK is a known pro-survival factor that can also have pro-
apoptotic role in cancers. Extensive ERK activity has been
observed in 84% of prostate cancer patients, 91% of head and
neck cancer cases, 67% of gastric cancers, and 72% of the breast
cancer population. However, others have shown that sustained
ERK activity can lead to apoptosis (Gioeli et al., 1999; Gee
et al., 2001; Murphy and Blenis, 2006). Also, P-ERKs have been
reported in 48% of renal and 58% of hepatocellular carcinoma
cancerous samples, respectively (Oka et al., 1995; Ito et al.,
1998). Our computational modeling showed that stimulation of
GPR30 with tamoxifen, changed ERK activity in MCF-7 cells
(Supplementary Table S1). As already demonstrated in Figure 2,
the concentration and stability of the phosphorylated ERKs were
significantly greater in the tamoxifen-treated group than the
control group. Moreover, our simulation results demonstrate
that enhanced activity of GPR30 signaling pathway has a
considerable effect on MAPK pathway. Next, we took advantage
of RNA sequencing and qRT-PCR methods in order to describe
that MAPK pathway may play an important role in inducing
apoptosis in MCF-7 cells.
Finally, sensitivity analysis as a commonly used approach that
studies the response of system variables to changes in parameter
values, and can therefore be used to identify the key reactions and
species was carried out for PI3K, Raf1 active, ppMEK and ppERK
in the presence of tamoxifen. As shown in Figure 3 ppERK is
more sensitive than PI3K, Raf1 active and ppMEK in simulated
model.
Incubation of MCF-7 Cells With
Tamoxifen Results in a Dose-Dependent
Decrease in Viability
The metabolic activity of MCF-7 cells was investigated based on
the activity of enzyme succinate dehydrogenase. To accomplish
this, the MTT method was used to determine the relative viability
of the cells 48 h after incubation with different concentrations of
tamoxifen (60–460 µM), with a goal of inducing cell apoptosis.
Figure 4 shows a 50% decrease in the viability of the cells
incubated with 250 µM of tamoxifen.
Induction of Apoptosis in MCF-7 Cells
Incubated With Tamoxifen
Apoptosis induction was investigated using Annexin V and PI
staining. The stained cells were classified into 4 groups, including
Q1: Necrotic cells (Anx−, PI+), Q2: Late apoptotic cells (Anx+,
PI+), Q3: Early apoptotic cells (Anx+, PI−) and Q4: Normal
cells (Anx−, PI−). Incubation of MCF-7 cells with 250 µM
tamoxifen resulted in their accumulation mainly in the Q2
region. The late stage in apoptotic cells showed accumulation
of PI in the nucleus, and exposure of the phosphatidylserines
in the outer leaflet of plasma membrane. This indicates that
after 48 h, the number of the cells in late apoptotic phase
had a significant increase from 0.045% in the control to
45.7% in cells incubated with tamoxifen. Therefore, induction
of apoptosis was confirmed in MCF-7 cells incubated with
tamoxifen (Figure 5).
Cell Cycle Assessments
Our studies did not show any significant changes in the cellular
distributions during different phases of the cell cycle (G1, S, G2)
compared with control. Thus, emphasizing that the 50% decrease
in cell viability after 48 h of incubation with tamoxifen did not
originate from cell cycle arrest (Figure 6). Incubation of the cells
with tamoxifen resulted in a 10% increase in the S phase and
6% in the G2 phase populations. These results suggest that the
tamoxifen mediated reduced cell viability is not mediated by cell
cycle arrest.
Quality Evaluation of RNA Sequencing
Data and Read Mapping
Q-score analysis showed that the quality of RNA-seq data had
the required standards and can be used for further analysis.
In addition, the N-base content was at the acceptable range of
sequence data and well filtrated for further analysis. For RNA
sequencing contents, we prepared two cDNA libraries (each
consisted of two biological replicates) of tamoxifen-treated MCF-
7 cells and control group. The libraries were sequenced using the
Illumina HiSeq platform technology (BGI, China) and in total,
130,791,283 raw reads were obtained. After removing adapters
and low-quality readings, we obtained 122,193,815 usable reads
(Table 1). Next, the refined data were aligned with the human
genome.
Differentially Expressed Genes (DEGs)
The cuffdiff and DESeq programs were used to determine
the DEGs in tamoxifen-treated and untreated cells. The gene
expression levels were considered statistically meaningful if
q-values were <0.01. The data showed that from 4,710
genes with differential expression levels 2,713 genes were
upregulated in tamoxifen-treated MCF-7 cells compared with
controls (Supplementary Table S2). A total of 65 genes
were apoptotic intermediates, especially in the Tp53 signaling
pathway, and some of them including MAP2K2 and MAPK6
are involved in cell growth (Supplementary Table S2). In
addition, down regulation of RARA, GREB and ESR1 (ER-
alpha) genes was observed. These genes have key roles in
classic Estrogen signaling pathways (Supplementary Table S3),
thus, indicating that Tamoxifen can lead to apoptosis and
cell death not only via modulation of the classic Estrogen
signaling pathway but also by transcriptional activation of
growth signaling pathways through GPR30 signaling axis, Next,
the DEGs were subjected to functional annotation and qPCR
verification.
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FIGURE 2 | The kinetics of phosphorylation and activation of ERK protein. The activating phosphorylation of ERK (ppERK) was enhanced under tamoxifen
stimulation. Control (Untreated cells): Green graph; Tamoxifen-treated cells: Red graph.
FIGURE 3 | Sensitivity analysis of Raf1 active, PI3K, ppMEK and ppERK. Calculation the sensitivity of Raf1 active, PI3K, ppMEK and ppERK (X-axis) with respect to
tamoxifen (Y-axis) which represented the highest sensitivity for ppERK.
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FIGURE 4 | The relative viability of MCF-7 cells incubated with various concentrations of tamoxifen. The viability of the treated cells is shown to be different from the
control in the presence of different concentrations of tamoxifen (60–460 µM). The incubation time of the treatments was 48 h. It can be seen that 50% decrease in
the viability of the cells can be achieved approximately with 250 µM of tamoxifen and this is utilized in conjunction with all treatments here for induction of apoptosis
in the cells.
FIGURE 5 | The impact of tamoxifen on apoptosis of MCF-7 cancer cells. Quadrants were drawn based on FSC/SSC plot in the untreated cells. Percent apoptosis
was determined using two dimensional plot of PI (PI, Y-axis) and Annexin V-FITC (X-axis). (Left) Treated cells with a single dose of tamoxifen (250 µM), and (Right)
the untreated control. Different cellular distributions are shown in the quadrants, Q1, necrotic cells; Q2, late apoptotic cells; Q3, early apoptotic cells; and Q4, normal
cells.
Gene Set Enrichment Analysis Using
Gene Ontology (GO) Classification and
KEGG Mapping
Using DAVID and GO functional enrichment analysis, we
classified the DEGs data into three groups including biological
process, cellular component, and molecular function. These
results showed that 65 identified overexpressed genes belonged to
the pro-apoptotic factors (p-value < 1.6E-05, q-value < 0.0007),
of which 37 genes were involved in intrinsic apoptosis
(p-value< 0.0002, q-value< 0.006) (Supplementary Table S4).
The KEGG database1 is designed to investigate the molecular
interactions and signaling networks in cells. In order to
1http://www.genome.jp/kegg
identify the activated signaling pathway in tamoxifen-treated
MCF-7 cells, the DEGs data were mapped to the KEGG,
and 24 signaling pathways were identified (q-value < 0.01).
The Tp53 signaling pathway was one of the pathways that
was allocated to a large number of DEGs (p-value < 0.0003,
q-value < 0.008). Based on the results in Supplementary
Table S5, a total of 19 DEGs (CDKN1A; GADD45B; GADD45A;
GORAB; TNFRSF10B; RCHY1; PPM1D; GADD45G; CASP8;
ZMAT3; CASP3; SESN1; SESN2; FAS; CYCS; PMAIP1; MDM4;
SFN; TP53) of the Tp53 signaling pathway were upregulated
by tamoxifen stimulation, and could mediate cell apoptosis. On
the other hand, the level of extrinsic apoptotic intermediates
including SMAD3, NF-1, BCL-2, BOK, KIAA0141, ITGAV, JAK3,
LMNA and RET were downregulated in tamoxifen-treated MCF-
7 cells, which suggest that the Tp53 signaling pathway is the main
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FIGURE 6 | Study of the cell distribution in different cell cycle stages. (Left) MCF-7 cells incubated with tamoxifen, and (Right) control cells. The bell-shaped curves
from left to right correspond to the G1, S, G2/M phases of the cell cycle in the control and cells incubated with tamoxifen. Incubation of cells with tamoxifen did not
significantly shift the distribution of the cells in different phases of the cell cycle compared with control. As in the treated group, there were minor increases, about 10
and 6%, in the S and G2 phases of the cell cycle, respectively.
TABLE 1 | Evaluation of valid reads mapped to the reference genome of each sample.
Sample name All reads Concordantly 1 Concordantly more 1 Discordantly 1 Discordantly more 1 Overall alignment rate
1 Untreated-1 31352452 11554043 14362527 980616 2715057 89.34%
2 Untreated-2 39295796 15364770 17495732 1241430 2785415 90.08%
3 Tamoxifen-treated-1 33269977 8829978 16689260 1157647 3948253 84.97%
4 Tamoxifen-treated-2 26873058 9399729 12375253 920064 2374041 87.91%
pathway by which intrinsic apoptosis transduces signals in order
to trigger cell death.
Real-Time PCR Verification of DEGs
In our ODE model, we showed that tamoxifen can engage the
Ras/MAPK pathway through GPR30, triggering the activation
of ERKs along with Tp53 mediated apoptosis pathway. Besides
inducing the apoptosis intermediates, the expression level of the
MAP2K2, CRAF and ERK3, which are involved in the MAPK
signaling cascades, were also upregulated (Figure 7).
We verified the data obtained from RNA-seq analysis for 8
DEGs using the qPCR method (Table 2). As shown in Table 2,
Bak1, PUMA, ERK3 and MAP2K2 genes were upregulated in
MCF-7 cells incubated with tamoxifen. However, the MAPK3
expression level was not significantly altered. Also, the expression
of genes such as ESR1(ER-alpha), GREB and RARA was
decreased. Taken together, these observations were in line with
RNA-seq results and confirmed the reliability of our ODE model,
which indicated that Tamoxifen can also stimulate apoptotic cell
death through increasing the magnitude of ERK activation and
deregulation of cell growth intermediates.
DISCUSSION
Estrogen is an important hormone in mammalian biology
which exerts its effects on a diverse array of target tissues via
genomic and non-genomic mechanisms (Filardo et al., 2002;
Prossnitz and Maggiolini, 2009). It has been shown that GPR30
can mediate estradiol proliferative effects in thyroid (Vivacqua
et al., 2006a), endometrial (Vivacqua et al., 2006b), ovarian
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FIGURE 7 | Analysis of the expression level of intended DEGs using qPCR. Bak1, PUMA, ERK3 and MAP2K2 genes were overexpressed in tamoxifen-treated
MCF-7 cancer cells, while the expression level of MAPK3 was not significantly changed. On the contrary, ER (ESR1), GREB and RARA were depressed under
tamoxifen induction. Each value is the mean ± SD of three separate experiments. The statistical significant differences are indicated with ∗ for p < 0.05.
TABLE 2 | qPCR analysis of the desired genes.
Gene Type Expression Standard error 95% C.I. P(H1) Result
GAPDH REF 1.000
MAPK3 TRG 4.942 4.771 – 5.119 4.731 – 5.161 0.162
ER (ESR1) TRG 0.110 0.092 – 0.131 0.089 – 0.135 0.000 DOWN
GREB TRG 0.128 0.109 – 0.151 0.104 – 0.158 0.000 DOWN
RARA TRG 0.498 0.435 – 0.570 0.435 – 0.570 0.000 DOWN
ERK3 TRG 5.836 2.637 – 12.928 2.578 – 13.215 0.000 UP
BAK1 TRG 1.879 1.520 – 2.323 1.508 – 2.342 0.000 UP
PUMA TRG 3.811 2.816 – 5.171 2.698 – 5.386 0.000 UP
MAP2K2 TRG 1.575 1.283 – 1.933 1.276 – 1.943 0.000 UP
P(H1), probability of alternate hypothesis that difference between sample and control groups is due only to chance. TRG, target; REF, reference.
(Albanito et al., 2007) and GPR30-positive SKBr3 breast cancer
cell lines (Albanito et al., 2008). In this work we utilize the heat-
inactivated FBS to diminish the estrogen concentration. There
has been some evidence regarding the ability of GPR30 to interact
with low levels of estrogens leading to PI3K and MAPK activation
(Filardo et al., 2000, 2002). Further, it has been shown that GPR30
is required for estrogen-induced activation of the MAPKs, ERK-1
and ERK-2. Additionally, estrogen-mediated ERK1/2 activation
through GPR30 pathway is transient and rapidly returning to
basal levels 10–15 min after exposure to estrogen (Filardo et al.,
2002). It is also worth pointing out that, we have compared
the gene expression profile between the tamoxifen-treated and
untreated cells, thus, the interference effects of the residual
estrogen for each group should be similar.
Tamoxifen, a potent anticancer agent known to interrupt
the enhanced estrogen activity of malignant mammary gland
cells, is used in women with breast cancer or at risk of
developing it (Larosche et al., 2007; Zheng et al., 2007). Tamoxifen
treatment displayed inhibitory effects on HeLa cell multiplication
at lower concentrations and toxicity at higher concentrations
and longer treatment durations. Cytological observations also
showed nuclear condensation, cell shrinkage, multinucleation,
and apoptotic bodies (Majumdar et al., 2001). Moreover, the
tamoxifen induced reduction of cell viability in HepG2 cells
depends on drug concentration and cell density and is due to
cytostatic and cytocide effects (Brandt et al., 2004). It was also
shown that tamoxifen (50, 100, 200, or 250 µM) inhibited CPT-
I activity by 38, 43, 58, and 64%, respectively (Larosche et al.,
2007).
The GPR30 receptor is a membrane ER-like protein
that actives intracellular signaling mediators, such as ERKs
(Filardo et al., 2000; Migliaccio et al., 2010; Ge et al., 2014;
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Wei et al., 2014). Recently, many investigators have reported that
GPCRs such as GPR30, enhance the MMPs mediated HB-
EGF protein release, and initiate the EGFR signaling. Also,
the Gβγ complex, formed in response to GPCRs activation,
stimulates the Src and Shc function and activate RTKs (Luttrell
et al., 1999; Filardo et al., 2000; Filardo, 2002; Prossnitz and
Maggiolini, 2009). Apart from the RTKs, GPCRs also have the
ability to activate ERKs in an alternative manner by stimulating
mononuclear GTPases such as Ras or Rap proteins (Belcheva and
Coscia, 2002; Bouschet et al., 2003; New and Wong, 2007).
The activation of ERKs is associated with many classical
apoptotic interactions such as activation of Caspase-3, PARP-1
cleavage, accumulation of phosphatidylserine in the membrane,
and aggregation and fragmentation of genomic DNA (Wang
et al., 2000; Alexia et al., 2004; Lee et al., 2005, 2006; Liu et al.,
2008). Considering the types of cells and the undertaken damage,
the activity of the Ras/Raf/ERK signaling pathway may lead to
the release of cytochrome c from mitochondria and activation of
caspase-9, or alternatively, stimulate extrinsic apoptotic pathway
that relies on the caspase-8 activity (Wang et al., 2000; Nesterov
et al., 2004; Schweyer et al., 2004; Zhang et al., 2004; Basu and
Tu, 2005; Wu et al., 2005). The activated ERKs can be located in
the mitochondrial membrane, and by disrupting could cause the
release of cytochrome c to the cytoplasm (Nowak, 2002; Nowak
et al., 2006; Zhuang et al., 2007). Also, ERK-dependent over-
activation of Tp53 protein, leads to phosphorylation of serine 15
in p53, inhibits its interaction with Mdm2 resulting in stability
and accumulation of Tp53 (Persons et al., 2000; She et al., 2000;
Yeh et al., 2004).
Bcl-2 family proteins have also an important role in the
cytochrome c excretion and induction of the inherited apoptosis.
The activation of MEK/ERKs increases the expression of pro-
apoptotic members of the Bcl-2 family including Bax, PUMA
and Bak. On the contrary, it depresses the anti-apoptotic
members of the Bcl-2 family, such as Bcl-2 itself and Bcl-
XL (Li et al., 2007; Liu et al., 2008; Panaretakis et al., 2008).
Additionally, the activity of Bcl-2 family is significantly regulated
by the Tp53 protein. ERK can induce the phosphorylation of
threonine 55 in Tp53, enhance its binding to the DNA, and
down regulate Bcl-2 expression (Persons et al., 2000; She et al.,
2000).
Many evidence suggest that estrogen signaling could be
mediated by the GPR30 as well as ER receptors. Tamoxifen,
an agonist for GPR30 receptors, is widely used as a selective
estrogen receptor (SERM) in treating hormone-dependent breast
cancer (Thomas et al., 2005; Jordan, 2006; Prossnitz et al., 2008).
We simulated the activity of the GPR30/PI3K/MAPK signaling
pathway in the onset of tamoxifen induced apoptosis within
MCF-7 cells. Our experiments depicted that the expression
level of 4,710 unique genes was altered in the presence of
tamoxifen. The GO analysis showed that many of the marked
genes play an active role in cell apoptosis pathways. For example,
65 genes were associated with the apoptotic signaling pathway
(GO:0097190). Also, 37 genes related to intrinsic apoptotic
signaling pathway (GO:0097193) were upregulated. On the
other hand, 22 genes have a positive role in cell growth
(GO:0030307), which demonstrates the impact of deregulated
growth signaling pathways on initiation of apoptosis in cells
incubated with tamoxifen (Supplementary Table S4). However,
this theory needs further examinations. The KEGG analysis
showed that many signaling pathways, including the p53
pathway, were significantly affected with tamoxifen treatment.
In addition to a significant increase in the expression levels
of the Tp53 signaling intermediates, such as Bak and PUMA,
the expression of ERK3 and MAP2K2 genes, involved in the
MAPK signaling pathways, were also increased. Furthermore,
decreased expression of genes such as ESR1 (ER-alpha), RARA
and GREB (Figure 7) suggests that the cytotoxic effects of
tamoxifen were not only mediated by disabling the ER and
some related factors, but most likely mediated through the
GPR30/PI3K/MAPKs interactions, ERK activation, and finally
the intrinsic apoptosis mediated by Tp53 (Supplementary
Table S2).
In this study, a mathematical model was developed for the first
time to assess the cross-talk between the GPR30, EGFR, PI3K and
STAT signaling pathways in the presence or absence of tamoxifen
(Supplementary Table S1). These four biological processes
are considered as main pathways during cell proliferation
process. Thus, any alterations in their expression or function
can lead to cell death. Based on the RNA-seq analysis, the
expression level of many MAPK pathway mediators, including
MAP2K2, Myc, MAPK6, JUN, and Raf-1, were increased in the
treated cells (Supplementary Tables S2, S6). Also, the designed
model of these four pathways showed an enhancement in the
level of activating phosphorylation of MAPKs by tamoxifen
stimulation.
CONCLUSION
In summary, this study showed that the apoptotic effects of
tamoxifen on MCF-7 cells were mediated through activation
of important signaling pathways including Tp53 and MAPKs,
and induction of intrinsic apoptosis. Our simulation and
transcriptomics analysis also showed that GPR30 activation may
have a potential role in the activation of MAPK pathway and it
is predicted that GPR30/PI3K/MAPK/STAT axis may be crucial
for induction of apoptosis in MCF-7 cell lines. Based on these
investigations, we claimed that GPER pathway might be involved
in toxicity of tamoxifen in ER positive MCF-7 cells. In addition
to enhancing our systematic understanding of the efficacy of
tamoxifen in treating breast cancer, this study introduced the
signaling pathways that impact the progression or prevention of
the breast cancer development and metastasis.
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